PHARMACOTERAPEUTIC IMPLEMENTATION OF THE USE LIREGLUTIDE

Abstract

DM2 is a type of diabetes that occurs due to insufficient insulin production by pancreas. Among the pharmacological therapy for DM2 are analogues to glucagon-like peptide 1 (GLP-1), which belongs to the incretin hormone class, whose activity is exerted at the gastrointestinal level after food ingestion, increasing insulin secretion according to the amount of glucose contained therein. Liraglutide is a GLP-1 receptor agonist and its main adverse reactions are nausea and vomiting and bodily, it acts by improving cardiovascular damage and mortality rates in patients with T2DM at high risk of cardiovascular disease. This is an integrative literature review. Thirteen articles were found in the literature, which met the inclusion and exclusion criteria. It was seen that most patients are composed of children and adults up to the age of 50, with a predominance of females and whites. Adverse effects from the use of liraglutide affect the gastrointestinal system, causing nausea, vomiting and abdominal distension. Pharmacotherapeutic follow-up is of paramount importance, because it allows the promotion of health education, resolution of health problems related to pharmacotherapeutic adherence. In this way, the pharmacist assists obese patients with the use of antidiabetic drugs through health education actions, active dispensing, monitoring and management of pharmacotherapy, with the purpose of reducing the misuse of this type of drug as an appetite suppressant.